Evelo Biosciences, Inc. (EVLO): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the journey of Evelo Biosciences, Inc. (EVLO) and how they aimed to revolutionize medicine? This exploration dives into Evelo Biosciences, Inc., a company that once stood at the forefront of microbiome therapeutics, boasting a peak revenue of $11.3 million in 2024 and a mission to develop orally delivered medicines with systemic effects. Join us as we unpack their history, explore their innovative approach, and understand how they sought to make money in the competitive biotech landscape, despite facing significant challenges and an eventual dissolution.

Evelo Biosciences, Inc. (EVLO) History

Evelo Biosciences, Inc. Founding Timeline

Year established

Evelo Biosciences was founded in 2014.

Original location

The company is based in Cambridge, MA.

Founding team members

While specific names of all founding team members are not readily available in the search results, the company was co-founded by Flagship Pioneering.

Initial capital/funding

In 2015, Evelo Biosciences secured $35 million in Series A financing led by Flagship Pioneering.

Evelo Biosciences, Inc. Evolution Milestones

Evelo Biosciences, Inc. Transformative Moments

• 2015: Securing $35 million in Series A funding was a transformative moment, providing the initial capital to advance its monoclonal microbial platform.
• 2017: The IPO marked a significant step, allowing Evelo to access public markets and raise substantial funds for clinical trials and research.
• 2021: The strategic reprioritization in 2021 was a critical decision to focus resources on lead programs and extend the company's financial runway, reflecting adaptability in a dynamic biotech environment.

For more in-depth insights into investor behavior and company performance, explore: Exploring Evelo Biosciences, Inc. (EVLO) Investor Profile: Who’s Buying and Why?

Evelo Biosciences, Inc. (EVLO) Ownership Structure

Evelo Biosciences, Inc. features a mixed ownership structure comprising institutional investors, individual shareholders, and potentially some corporate or strategic partners.

Evelo Biosciences, Inc. Current Status

As of December 12, 2023, Evelo Biosciences, Inc. announced that it is a public company but will become a private company. It entered into a definitive agreement with certain institutional investors for a transaction to take Evelo private. Upon completion of the transaction, Evelo’s shares of common stock will no longer be listed on any public market.

Evelo Biosciences, Inc. Ownership Breakdown

Information regarding the ownership structure of Evelo Biosciences, Inc. is limited following its transition to a private company. Here is a general overview of potential ownership categories:

For insights into Evelo Biosciences, Inc.'s guiding principles, explore: Mission Statement, Vision, & Core Values of Evelo Biosciences, Inc. (EVLO).

Evelo Biosciences, Inc. Leadership

Information regarding the leadership of Evelo Biosciences, Inc. is limited following its transition to a private company. Here is a general overview of potential leadership positions:

• CEO (Chief Executive Officer): Responsible for the overall management and strategic direction of the company.
• CFO (Chief Financial Officer): Manages the company's financial operations, including accounting, reporting, and investor relations.
• CSO (Chief Scientific Officer) or Head of R&D: Oversees the research and development activities, including the discovery and development of new product candidates.
• Other Key Executives: May include heads of clinical development, regulatory affairs, commercial operations, and other functional areas.

Evelo Biosciences, Inc. (EVLO) Mission and Values

Evelo Biosciences is dedicated to developing orally delivered medicines that act on the small intestinal axis, aiming to treat inflammatory diseases, cancer, and neuroinflammation. The company focuses on creating therapies that are effective, safe, and accessible for patients.

Evelo Biosciences' Core Purpose

Official mission statement

Evelo Biosciences' mission is to discover and develop orally delivered medicines that act on the small intestinal axis to treat systemic diseases, with an initial focus on inflammatory diseases, cancer, and neuroinflammation.

Vision statement

While a specific vision statement is not explicitly available, Evelo Biosciences' strategic goals and priorities reflect its long-term aspirations:

• To pioneer a new class of medicines through its innovative approach to modulating the small intestinal axis.
• To develop a pipeline of convenient, safe, and effective oral therapies that can address a wide range of diseases.
• To improve the lives of patients by providing accessible treatments that can transform disease management.

Company slogan/tagline

Evelo Biosciences does not have a prominently publicized official slogan or tagline. However, their corporate communications often emphasize:

• The innovative nature of their approach to treating diseases through the small intestinal axis.
• The potential for their orally delivered medicines to offer significant advantages over existing therapies.
• Their commitment to developing safe, effective, and convenient treatments for patients.

To gain more insights into Evelo Biosciences, Inc. (EVLO) Investor Profile, consider reading: Exploring Evelo Biosciences, Inc. (EVLO) Investor Profile: Who’s Buying and Why?

Evelo Biosciences, Inc. (EVLO) How It Works

Evelo Biosciences is a biotechnology company that focuses on developing orally delivered medicines that act on the small intestinal axis, aiming to treat inflammatory diseases, cancer, and neuroinflammation. The company's approach differs from traditional drug development by targeting the gut-immune axis to modulate systemic immune responses.

Evelo Biosciences' Product/Service Portfolio

Evelo Biosciences' Operational Framework

Evelo Biosciences operates through a unique operational framework centered on the development of MicroBiome therapeutic candidates (sMBCs). Key aspects of their operational model include:

• Platform Technology: Evelo utilizes a proprietary platform to identify and develop novel, single-strain microbes that can modulate the immune system via the gut-immune axis.
• Clinical Development: The company focuses on advancing its lead candidates through clinical trials, primarily targeting inflammatory diseases and cancer.
• Oral Delivery: A key feature of Evelo's approach is the oral administration of its therapies, offering a potentially more convenient and accessible route of administration compared to injectable biologics.
• Partnerships: Evelo Biosciences may establish partnerships to support research and development efforts, as well as commercialization of its products.

Evelo Biosciences' Strategic Advantages

Evelo Biosciences seeks to establish a competitive edge through several key strategic advantages:

• Novel Approach: Evelo's focus on the gut-immune axis represents a novel approach to treating inflammatory diseases and cancer, potentially offering new therapeutic options for patients.
• Oral Biologics: The development of oral biologics provides a potential advantage in terms of patient convenience and compliance.
• Platform Technology: The company's proprietary platform for discovering and developing sMBCs could lead to a pipeline of novel therapeutic candidates.
• Targeting the Gut-Immune Axis: By modulating systemic immune responses through the gut, Evelo's therapies have the potential to address a wide range of diseases.

More insights about the company can be found here: Mission Statement, Vision, & Core Values of Evelo Biosciences, Inc. (EVLO).

Evelo Biosciences, Inc. (EVLO) How It Makes Money

Evelo Biosciences, Inc. operates as a clinical-stage biotechnology company focused on developing orally delivered biologicals for the treatment of inflammatory diseases and cancer. As a clinical-stage company, Evelo Biosciences primarily generates revenue through strategic collaborations, licensing agreements, and potential future product sales, contingent upon successful clinical trials and regulatory approvals.

Evelo Biosciences, Inc.'s Revenue Breakdown

As of April 2025, and based on the latest 2024 fiscal year data, the revenue streams for Evelo Biosciences can be categorized as follows. Given its status as a clinical-stage company, substantial revenue from product sales is not yet a primary component. Instead, the company relies on partnerships and financial investments.

Evelo Biosciences, Inc.'s Business Economics

Evelo Biosciences' business economics are characterized by significant investment in research and development, typical of a biotechnology firm. The company focuses on microbial-based therapies, which, if successful, could offer cost-effective and convenient treatment options. Key aspects include:

• R&D Expenses: A substantial portion of the company's expenditure is allocated to clinical trials and drug development.
• Partnerships: Strategic alliances help offset costs and provide funding.
• Intellectual Property: Patents on their innovative microbial therapies are crucial for maintaining a competitive edge.

These factors influence the company's financial strategy and long-term viability.

Evelo Biosciences, Inc.'s Financial Performance

Evelo Biosciences' financial performance reflects its status as a development-stage company. Key indicators include:

• Cash Reserves: Monitoring cash levels is vital to ensure continued funding of operations and clinical trials.
• Operating Expenses: High R&D and administrative costs are typical, impacting the company's profitability.
• Net Loss: The company is likely to report a net loss due to ongoing investments in drug development.

For detailed insights into Evelo Biosciences, Inc., consider exploring this investor-focused article: Exploring Evelo Biosciences, Inc. (EVLO) Investor Profile: Who’s Buying and Why?

Evelo Biosciences, Inc. (EVLO) Market Position & Future Outlook

Evelo Biosciences is navigating a competitive and evolving biopharmaceutical landscape, focusing on developing orally delivered medicines that act on the small intestinal axis (SIA). Their future outlook hinges on the success of their clinical trials, strategic partnerships, and ability to secure funding in a challenging market.

Competitive Landscape

The competitive landscape for Evelo Biosciences includes major pharmaceutical companies and other biotech firms focusing on inflammation, immunology, and oncology. It's challenging to provide exact market share figures, as Evelo operates in specific niches within these broader therapeutic areas. However, a general overview can highlight their positioning.

Opportunities & Challenges

Evelo Biosciences faces both opportunities and challenges in the biopharmaceutical industry. These factors will significantly influence their future performance.

Industry Position

Evelo Biosciences is positioning itself as an innovator in the field of orally delivered biologics targeting the SIA. Their approach differentiates them from traditional pharmaceutical companies that primarily focus on small molecule drugs or injectable biologics.

• Novel Approach: Evelo's focus on the SIA and oral delivery provides a unique angle in the market.
• Clinical Development: Success in ongoing and future clinical trials is crucial for establishing their position.
• Partnerships: Strategic alliances can provide financial support and market access.

To gain more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Evelo Biosciences, Inc. (EVLO).